Highlights Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
22.17 ^USD	+0.18%		-5.62%	+7.62%

03-03	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-26	Neurogene announces FDA breakthrough therapy designation for NGN-401 gene therapy for Rett syndrome	RE

Highlights

03-03	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
02-26	Neurogene Inc. Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome	CI
02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI
11-13	Gene therapy developer Neurogene's Q3 net loss widens	RE
11-13	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Neurogene Inc. Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome Multidomain	CI
11-06	Neurogene Inc. Announces First Participant Dosed in Embolden?? Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome	CI
09/10/25	Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025	CI
03/10/25	Neurogene announces inducement grants under Nasdaq Listing Rule	RE
05/09/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
11/08/25	Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/08/25	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
30/06/25	Neurogene Inc. Announces Registrational Trial Design for Embolden? Study of NGN-401 Gene Therapy for Rett Syndrome	CI
16/05/25	Neurogene Inc. Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV	CI
09/05/25	Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/04/25	Neurogene Inc. Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate Ngn-401 with Exact?? Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome	CI
24/03/25	Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/11/24	Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
18/11/24	Neurogene Inc. Provides Update on Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome	CI
18/11/24	Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy	MT
12/11/24	Investor Sentiment Muted as Inflation Report Looms, Driving Quiet Premarket Action for US Equity Futures	MT
12/11/24	Top Premarket Decliners	MT
11/11/24	Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome	CI
12/08/24	Neurogene Inc. Announces NGN-401 Receives Regenerative Medicine Advanced Therapy Designation from the U.S. Food and Drug Administration for the Treatment of Rett Syndrome	CI